Conference item : Abstract
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group Limited Publisher's website
- Journal:
- Annals of the Rheumatic Diseases Journal website
- Volume:
- 77
- Pages:
- 1010-1011
- Host title:
- Annals of the Rheumatic Diseases
- Publication date:
- 2018-06-12
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Source identifiers:
-
930945
Item Description
- Keywords:
- Subtype:
- Abstract
- Pubs id:
-
pubs:930945
- UUID:
-
uuid:34a929e9-eee5-4bfc-ab8d-f37def274b76
- Local pid:
- pubs:930945
- Deposit date:
- 2019-06-06
Terms of use
- Copyright holder:
- Nash et al
- Copyright date:
- 2018
- Notes:
- © 2018, Published by the BMJ Publishing Group Limited. This abstract was presented on the Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, June 13-16, 2018.
If you are the owner of this record, you can report an update to it here: Report update to this record